Argenx, NL0010832176

Argenx stock after-hours at EUR 840.00: minus 0.70 percent versus prior close at Lang & Schwarz

Published on 10/01/2026 at 21:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock was at EUR 840.00 after-hours at 9:41 p.m. CEST on October 1, 2026, according to Lang & Schwarz. The price was down 0.70 percent versus the prior close.

Redaktionelles Börsenfoto: Leuchtende Handelsdisplays mit grünen Aufwärtskurven im Biotech-Sektor, verschwommener Handelssaal im Hintergrund, Atmosphäre des Finanzjournalismus
Argenx NL0010832176 leuchtende Handelsbildschirme an der Euronext zeigen steigende grüne Kurven für Biotech-Aktien, Illustration mit AI erstellt.

Argenx stock was at EUR 840.00 after-hours at 9:41 p.m. CEST on October 1, 2026, according to Lang & Schwarz. The price was down EUR 5.90, or minus 0.70 percent, versus the prior close of EUR 845.90 at Lang & Schwarz.

After-hours trading

The latest euro price was recorded after the Xetra close, with the bid at EUR 839.40 and the ask at EUR 840.60. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Argenx stock.

New VYVGART data presented

In a September 29 release, argenx SE said it would present clinical, long-term and real-world data at the AANEM Annual Meeting and MGFA Scientific Session in Orlando through October 2. The company reported that a real-world analysis of more than 1,100 U.S. patients with myasthenia gravis found the greatest gains among patients who started VYVGART earlier. Patients treated within one year of diagnosis had a mean MG-ADL reduction of 4.7 points over three months, compared with 3.5 points for patients treated more than three years after diagnosis. In chronic inflammatory demyelinating polyneuropathy, argenx said VYVGART Hytrulo reduced the relative risk of grip-strength deterioration by 71.5 percent in a post hoc analysis.

Disclaimer...

en | NL0010832176 | ARGENX | boerse | 70212995 | bgmi